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1. Introduction
1.1. Lung cancer – Stadialization
Lung cancer is responsible for 1.3 million deaths worldwide annually, and it is the most
common cause of cancer-related death in men and the second most common in women.
Lung cancer staging is the assessment of the degree to which a lung cancer has spread from
its original source. As with most cancers, for lung cancer staging is of paramount impor‐
tance for the treatment planning process and prognosis. Two primary methods of lung can‐
cer staging are available: clinical staging and pathologic staging. In clinical staging,
information is provided by noninvasive or minimally invasive techniques, such as physical
examination, radiologic examination, endoscopic ultrasound, bronchoscopy, mediastinosco‐
py, and thoracoscopy. In pathologic staging, information obtained from clinical staging is
combined with findings from both the invasive surgical procedure and the pathologic evalu‐
ation of excised tissue. Clinical staging is important and can help to determine the next ap‐
propriate step in therapy, such as the decision to proceed with pathologic staging, which
remains the reference standard because the overall level of agreement between the two sys‐
tems only ranges from 35% to 55% [1].
Definition of the stage is an essential part of the approach to patients with lung cancer, and
it has led to the development of a universally accepted stage classification systems for most
tumors. The Union Internationale Contre le Cancer (UICC) and the American Joint Commit‐
tee on Cancer (AJCC) periodically define, review, and refine the stage classification systems.
Nearly half of all patients with lung cancer have mediastinal disease at diagnosis, and this
implies metastases to ipsilateral or subcarinal nodes (N2) that are classified as stage IIIA dis‐
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ease. Management of stage IIIA disease is more controversial, but many centers treat it with
radiation and chemotherapy, with surgery performed under investigational protocols. Di‐
rect mediastinal invasion (T4) or metastasis to contralateral mediastinal nodes (N3) is classi‐
fied as stage IIIB disease. The 5-year survival rate in this case is at best 5%, and patients are
generally offered treatment with chemoradiotherapy without surgery.
The previous tumor, node, and metastasis (TNM) classification, the sixth edition of the TNM
Classification of Malignant Tumors, was published in 2002. The last revision of the staging
system for lung cancer has been presented by Dr. Clifton Mountain in 1997 [2], after his pro‐
posal had been adopted in 1973 by the AJCC in the same year and by the UICC in 1974, and
this revision remained unaltered on the 2002 manual [3]. The 1973 original system was
based on a database of 2,155 patients from the MD Anderson Cancer Center in Houston, TX.
Subsequent revisions of the TNM staging system continued to be based on this database,
which grew to include 5,319 cases at the time the lung cancer staging system was revised in
1997 and it was also validated by Dr. Naruke from Japan in 2001. Mountain’s revision was
based on a relatively small population of patients who underwent surgical treatment in a
single geographic area, and no validation was presented to justify the individual descriptors
[4]. In order to overcome the limitations of the sixth TNM classification, the International
Association for the Study of Lung Cancer (IASLC) launched the Lung Cancer Staging
Project in 1996, and in 1998 created an International Staging Committee (ISC) of multidisci‐
plinary members to conduct revisions [5]. Changes to the sixth edition were proposed by the
IASLC based on an international collection and review of 100,869 patients from 46 sources of
20 countries. Data were drawn from lung cancer cases treated by all modalities between
1990 and 2000. After exclusion of ineligible cases, 81,015 patients (67,725 NSCLC and 13,290
SCLC) remained for investigation [6]. Proposals for revision were submitted to the AJCC
and UICC for consideration in the new edition of the staging manual, the 7th, and both ac‐
cepted the recommendations. In the last months of 2009, the Seventh Edition of the TNM
Classification of Malignant Tumors was published, with a new lung cancer staging system.
The new edition took effect on January 1, 2010 [7].
The changes recommended by the IASLC for the 7th edition of TNM classification for lung
cancer were based on differences in survival [8], and the results of the data analysis were
internally and externally validated [9]. These changes include new T and M definitions and
consequent new stage groupings, a new lymph node map, a novel definition on pleural in‐
vasion, as well as recommendations to apply the TNM system to broncho-pulmonary carci‐
noid tumors and SCLC.
The  success  story  of  EBUS-TBNA starts  in  2003  with  a  publication  in  Thorax  by  Mark
Krasnik and Peter Vilmann from Gentofte University Hospital, Denmark [10]. This article
gave the first description of the principle of EBUS-TBNA. In the same journal, in 2006, the
same group, together with a group from the Thoraxklinik in Heidelberg and Harvad Med‐
ical School’s Beth Israel Deaconess MC, published their study on 502 patients that showed
that EBUS-TBNA resulted in 93% diagnostic yield, a sensitivity of 94%, specificity of 100%
and  accuracy  94%,  with  PPV  at  100%  and  NPV  at  11%  [11].  In  2006,  an  international
EBUS-TBNA focus group was formed by Felix J.F. Herth (Copenhagen), Kazuhiro Yasufu‐
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ku (Chiba),  Robert Rintoul (Cambridge) and Armin Ernst (Boston) that published in the
Journal  of  Bronchology a  description of  how to  do an EBUS-TBNA thus  offering a  de‐
tailed description of  local  lymph node position and orientation within the mediastinum
[12]. EBUS-TBNA has been studied and compared also in relation with existing modalities
like EUS –FNA (by Vilmann et al. in 2005 on 33 pts. and by Herth et al. in 2005 on 160
pts.), PET-CT (by Yasufuku et al. in 2006 on 102 pts.), classical TBNA and EUS-FNA (by
Wallace et al. in 2008 on 138 pts.).
EBUS-TBNA was proven in 2007 by Wong and Yasufuku et al. on 65 patients to be a safe
method allowing a high yield also for the diagnosis of sarcoidosis [13].
It soon became widely accepted that EBUS-TBNA is a reliable diagnostic tool for enlarged
lymph nodes in patients with NSCLC and that lymph nodes below the one centimeter range
could also be sampled. This led to a study with 100 patients published in 2006 in European
Respiratory Journal [14] that showed that every sixth patient with no evidence of mediasti‐
nal disease on CT was diagnosed positive using EBUS-TBNA. Thus, EBUS-TBNA showed
potential to avoid unnecessary exploratory thoracoscopies. Following the same idea, in 2008
Hwangbo et al. showed that in cases with both CT- and PET-negative and –positive scans,
EBUS-TBNA is an excellent tool for detecting mediastinal metastasis, thereby confirming
that EBUS-TBNA is an effective invasive method following CT and PET scanning [15].
In the same year, Armin Ernst et al. showed in Journal of Thoracic Oncology on 66 patients
that EBUS-TBNA can have a superior yield compared to cervical mediastinoscopy, which
intuitively suggested that mediastinoscopy is not necessarily of additional diagnostic benefit
in evaluating negative EBUS-TBNA staged lymph nodes [16]. However, mediastinoscopy
has an important role especially in operable patients with non-enlarged lymph nodes for as‐
sessing local mediastinal invasion and the exclusion of metastatic disease.
Herth et al. evaluated EBUS-TBNA for re-staging in 124 patients with tissue-proven IIIA-N2
disease after induction chemotherapy (Journal of Clinical Oncology 2008) and concluded
that EBUS-TBNA is a valuable and practical tool for re-staging with a sensitivity of 76%,
specificity of 100%, PPV of 100%, NPV of 20% and diagnostic accuracy of 77% [17]. These
results imply that a negative EBUS-TBNA for re-staging should be surgically re-staged.
In 2006, the compatibility between EBUS-TBNA and the Aloka Prosound alpha5 ultrasound
processor made additional Doppler modes available, and this led to a consecutive study by
Herth et al. on 89 patients that described changes in flow resistance parameters (resistance
index by Pourcelot) in malignant lymph nodes [18].
Yasufuku et al. from Chiba University have shown great dedication to evaluating the ben‐
efits of EBUS-TBNA samples for immunohistochemical analysis and reported encouraging
results  with  cell  cycle-related  proteins  in  chemotherapy  patients  in  Thorax  2008,  and  a
year  earlier  in  Chest  the  same  group  showed  that  epidermal  growth  factor  receptor
(EGFR)  mutation  can  be  easily  detected  in  metastatic  lymph  node  samples  for  EBUS-
TBNA and so the samples gained by EBUS-TBNA allowed genetic evaluations of tumour
cells from lymph nodes [19, 20].
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In 2009 Tournoy et al. provided a detailed analysis of endosonographic landmarks (where
available), describing the anatomic borders of the lymph node stations as defined in the 7th
edition of the IASLC’s TNM-staging nomenclature, which is relevant for correctly staging
patients with lung cancer [21].
Building on the strong results of combined EUS-FNA and EBUS-TBNA procedures – a study
published by Vilman et al. in 2005 had already indicated their complementary nature – An‐
nema et al. challenged in 2010 the pre-dominant surgical staging algorithm by comparing
the combined EBUS-TBNA and EUS-TNA with surgical staging alone [22] and showed that
combining endosonographic and surgical staging resulted in greater sensitivity for mediasti‐
nal nodal metastases and fewer unnecessary thoracotomies. These results indicated that the
combination of both procedures may be able to replace surgical stages as the primary stag‐
ing method for patients with lung cancer.
Instead of using different scopes for EBUS-TBNA and EUS-TNA, two separate studies pub‐
lished in Chest in 2010 by Hwangbo et al. and Herth et al. [23] used only one bronchoscope
for both procedures, starting via the trachea and continuing via the oesophageal route. They
came to the conclusion that EBUS-TBNA and EUS-TNA are complementary methods and
showed that both procedures can be performed with a single EBUS echoendoscope in one
sitting by one operator. A further study in 2011, “Nonsurgical staging of the mediastinum:
EBUS and EUS” conducted by Herth, stated that the combination of both procedures ach‐
ieves a complete and accurate mediastinal staging. Therefore it can be expected that the im‐
plementation of combined EBUS-TBNA and EUS-FNA will reduce the need for surgical
staging of lung cancer significantly [24].
The summary of scientific studies on EBUS-TBNA provided about clearly shows the proce‐
dure’s power in helping to improve mediastinal staging of lung cancer during the past 10
years. The technological development of less invasive staging and sampling devices contin‐
ues endoscopists using endosonography, we can expect further exciting developments in
clinical practice in the years to come.
Endobronchial ultrasound with real-time-guided transbronchial fine-needle aspiration
(EBUS-TBNA) is a minimally invasive outpatient procedure by which mediastinal [25] and
hilar lymph nodes [26] as well as centrally located primary lung lesions [27] can be visual‐
ised and sampled under ultrasound guidance. In a systematic review, EBUS-TBNA has
shown a pooled sensitivity of 93% in the staging of non-small-cell lung cancer. In a direct
comparison with surgical staging, EBUS-TBNA even showed to be superior [28]. Therefore,
EBUS-TBNA has been adopted in the most recent lung cancer staging guidelines as a mini‐
mally invasive alternative to surgical staging [29]
EBUS-TBNA is an accurate, minimally invasive and safe staging procedure and can be con‐
sidered the procedure of choice for patients with extrathoracic malignancies in whom hilar
or mediastinal lesions are observed. In patients with (concurrent or previously treated) ex‐
trathoracic malignancy, EBUS-TBNA has a sensitivity of 85% to demonstrate metastatic
spread. Implementation of EBUS-TBNA in these patients obviates invasive surgical diagnos‐
tic procedures in 61%. [30, 31]
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The development and introduction of the new convex probe endobronchial ultrasound (CP-
EBUS) that performs endobronchial ultrasound-guided transbronchial needle aspiration has
changed the practice of bronchoscopic biopsy of the mediastinum in respiratory diseases. In
particular, the role of EBUS-TBNA in the diagnosis and mediastinal lymph node staging of
lung cancer, the leading cause of death from malignant disease worldwide [32], is becoming
an interest to pulmonologists as well as thoracic surgeons. The newest CP-EBUS now being
used in clinical practice is a hybrid bronchofibervideoscope which features a unique optical
system that exploits both video and fiber-optic technologies (BFUC160F- OL8, Olympus, To‐
kyo, Japan). This CP-EBUS is a linear curved array transducer that scans parallel to the in‐
sertion direction of the bronchoscope. Images can be obtained by directly contacting the
probe or by attaching a balloon on the tip and inflating with saline (Figure 1). The outer di‐
ameter of the insertion tube of the CP-EBUS is 6.2 mm, and that of the tip is 6.9 mm. The
angle of view is 80º and the direction of view is 35º forward oblique [33].
 
Figure 1. Tip of the new convex probe endobronchial ultrasound (CP-EBUS, BF-UC160FOL8, Olympus, Tokyo, Japan).
The outer diameter of the insertion tube of the flexible bronchoscope is 6.2 mm. CP-EBUS has a linear curved array
ultrasonic transducer of 7.5 MHz. The balloon attached to the tip of the bronchoscope is inflated with normal saline
(A). The dedicated TBNA needle is inserted through the working channel (B) [33].
The built-in CCD in the control section allows sharp images similar to those of regular vid‐
eoscopes and allows a slimmer insertion tube of 6.2 mm. The ultrasound images can be fro‐
zen and the size of lesions can be measured in two dimensions by the placement of cursors.
It is also equipped with the Color Power Doppler mode. The display range covers 2–24 cm
(Figure 2).
 
Figure 2. The convex probe endobronchial ultrasound (CP-EBUS, BF-UC160F-OL8, Olympus, Tokyo, Japan) and The
dedicated ultrasound processor (EU-C60/EU-C2000, Olympus, Tokyo, Japan) [33].
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The dedicated 22-gauge needle is used for EBUS-TBNA (Figure 3). The needle is a single use
aspiration needle with echogenic dimpled tip design to improve visibility on ultrasound im‐
ages. This needle has various adjuster knobs which work as a safety device to prevent dam‐
age to the channel. The maximum extruding stroke is 40 mm and to prevent excessive
protrusion, a safety mechanism stops the needle at the stroke of 20 mm. The needle is attach‐
ed onto the working channel of the bronchoscope which allows the operator to actually per‐
form EBUS-TBNA. The needle is also equipped with an internal sheath which is withdrawn
after passing the bronchial wall, avoiding contamination during TBNA. This internal sheath
is also used to clear out the tip of the needle after passing the bronchial wall. The use of this
sheath has significantly increased the yield of EBUS-TBNA. The exit of the needle is at 20°
with respect to the outer covering of the insertion tube. The needle can be visualized
through the optics and on the ultrasound image [33].
 
Figure 3. A Dedicated 22-gauge needle (NA-201SX-4022, Olympus, Tokyo, Japan) and the Vaclok syringe used to cre‐
ate negative pressure. B The needle attached to the working channel of the EBUS-TBNA bronchoscope. The maximum
extruding stroke is 40 mm and to prevent excessive protrusion, a safety mechanism stops the needle at the stroke of
20 mm [33].
Mediastinal staging can be divided into noninvasive staging (imaging) and invasive (sam‐
pling) staging. Computed tomography (CT), magnetic resonance imaging (MRI), positron
emission tomography (PET) and PET-CT are used for noninvasive imaging [34]. Other
imaging modalities include the use of transesophageal ultrasonography (EUS) and endo‐
bronchial ultrasound (EBUS) using a radial probe for detecting even small mediastinal
lymph nodes [35-36]. Mediastinoscopy is still the gold standard for mediastinal lymph node
staging [37]. However, it requires general anesthesia and complications cannot be ignored.
1.2. Changes to T descriptors [38-39]
Rami-Porta R et al. evaluated in 2007 for the 7th Edition of the TNM Classification of Malig‐
nant Tumors only patients without metastasis and, although there was information about
different aspects of the T component, they only could analyze in detail tumor size, existence
of accompanying nodules and pleural dissemination.
The prognostic value of the tumor size was studied in patients with completely resected
pathological T1 and T2 N0 M0 tumors who had not received adjuvant therapy. The statisti‐
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cal calculations determined three cut-points at 2, 5 and 7cm, which, in addition to the 3cm,
the border between T1 and T2, gave rise to 5 groups of tumors with significantly worse sur‐
vival with larger tumor diameters. The groups and their 5-year survival rates were: T1≤2cm,
77%; T1>2cm and ≤3cm, 71%; T2>3cm and ≤5cm, 58%; T2>5cm and ≤7cm, 49%, and T2>7cm,
35%. This prognostic gradation was maintained when less selective patient populations
were evaluated: clinical staging, incomplete resection and different lymph node affectation.
With such arguments, it was decided to subdivide the T1 tumors into T1a (≤2cm) and T1b
(>2cm and ≤3cm), and T2 tumors into T2a (>3cm and ≤5cm) and T2b (>5cm and ≤7cm). Like‐
wise, the 5-year survival was compared between patients with T2>7cm tumors and T3 tu‐
mors. Similar results were found in the different populations, except in the N0 cases with
complete resection, in which it was verified that the survival was even higher in the T3
(41%) than in the T2>7cm (35%), therefore it was decided to reclassify the latter as T3. When
they analyzed the tumors that, with pathological staging, presented additional nodules, it
was observed that: (a) the 5-year survival of the T3 (31%) was similar to the T4 classified as
such due to the existence of an additional nodule or nodules in the same lobe as the primary
tumor (28%); (b) the T4 due to other factors had the same survival as those classified as M1
due to an additional nodule(s) in a different homolateral lobe than the primary tumor (22%);
and (c) the T4 due to pleural dissemination had a clearly worse prognosis (11% 5-year sur‐
vival). For the new classification, it was therefore recommended to consider as T3 those tu‐
mors with additional nodule(s) in the same lobe as the primary tumor, to consider as T4
those tumors with additional nodule(s) in a homolateral lobe other than that of the primary
tumor, and to include in the M category those tumors with pleural dissemination (Table 1).
T descriptor 6th ed. 7th ed.
T size Tumors = 2 cm
T1
T1a
Tumors > 2 cm and = 3 cm T1b
Tumors > 3cm and = 5cm
T2
T2a
Tumors > 5 cm and = 7 cm T2b
Tumors > 7 cm T3
Separate nodule(s) in the primary lobe. T4 T3
Separate nodule(s) in a different ipsilateral lobe. M1 T4
Malignant pericardial effusion. T4 M1a
Pleural dissemination. T4 M1a
Table 1. T descriptor changes: comparison between 6th and 7th edition of the TNM Classification of Malignant
Tumors [38]
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1. Tumor size cut points at 2, 3, 5, and 7 cm:
• T1 subclassified:
- T1a: tumors = 2 cm
- T1b: tumors: > 2 cm and = 3 cm
• T2 subclassified:
- T2a: > 3cm and = 5cm
- T2b: > 5 cm and = 7 cm
• T2 reclassified:
- T2 > 7 cm became T3.
2. Multicentric tumors of similar histology:
- Separate nodule(s) in the primary lobe: became T3 from T4.
- Separate nodule(s) in a different ipsilateral lobe: became T4 from M1.
3. T4 descriptors:
- Pleural dissemination (pleural nodules or malignant effusion): became M1a from T4.
- Malignant pericardial effusion: became M1a from T4.
In the AJCC Cancer Staging Manual and UICC TNM Classification of Malignant Tumors the T
factor is divided into four descriptors (T1-4) depending on size, site, number, and local ex‐
tent of the primary tumor: the size and non-size based descriptors [40].
1.2.1. Size-based T descriptors
The value of tumor size in NSCLC prognosis is supported by large clinical evidence [41-45].
The tumor size threshold of 3 cm was set-up on the 2nd edition of the TNM classification of
malignant tumors in 1974.[46], and despite the advances in surgical procedures, adjuvant
treatment, and mostly in imaging technology, this measure remained unchanged for 35
years. The 7th edition of the TNM for lung cancer confers more importance to the size-based
T descriptors and divides them as seen earlier. These modifications have been validated by
recent studies that showed better survival stratification and prognosis estimation with the
new T definitions [47-49].
Table  2a  describes  lower  survival  rates  as  the  T  factor  increases  [50-51].;  survival  rates
are improved with the new system due to reclassification (up- and down-staging) of pa‐
tients when compared to series reporting survival rates with the previous TNM, showed
in Table 2b [52-53].
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T component
5-year survival (%)
Kameyama et al [25] Li et al [24]
T1a 82.6 75.49
T1b 73.3 74.58
T2a 63.5 60.87
T2b 50.1 55.63
T3 40.6 46.15
T4 34.6 NS
T component
5-year survival (%)
Mountain CF [26] Naruke et al. [27]
T1 67 68.9
T2 57 42.5
T3 38 31.9
T4 7 (cT) 18.9
Table 2. a. Five year survival by pT classification with the 7th edition. b. Five year survival by pT classification with the
6th edition [40].
1.2.2. Non–size-based T descriptors
1.2.2.1. Multiple nodules
The existence  of  multiple  primary cancers  (MPC) was initially  reported by Warren and
Gates  in  1932  [54],  but  in  spite  of  these  past  80  years,  to  date  accurate  diagnosis  of
MPC is not yet clearly established due to a lack of consensus on definition and diagnos‐
tic criteria [55]
In 1975, Martini and Melamed were the first to propose clinical and histopathologic criteria
for the differential diagnosis of second lung cancers [56]. MPLCs are defined synchronous, if
detected simultaneously, or metachronous, if tumors are separated in time [57-58]. Synchro‐
nous nodules may represent a MPLC (second primary), a metastasis, or an extension from
the primary (satellite nodule) [59] (Table 3).
Deslauriers et al. described in 1989 intrapulmonary nodular metastasis in patients with
NSCLC as satellite nodules, and the 5- year survival rates for these patients with satellite
nodules were 21.6% compared to 44% for patients without satellite nodules. They concluded
that patients with satellite nodules should be classified as stage IIIA [60].
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Type Definition
Satellite nodule Same histology
And same lobe as primary cancer
And no systemic metastasis
MPLCs Same histology, anatomically separated Tumors in different lobes
And no N2-3 involvement
And no systemic metastasis
Same histology, temporally separated =4-yr interval between tumors
And no systemic metastasis from either tumor
Different histology Or different molecular genetic features
Or arising separately from foci of CIS
Metastasis Same histology With multiple systemic metastasis
Same histology, in different lobes And presence of N2-3 involvement
Or < 2-yr interval
Table 3. Definitions of second primary, satellite nodules and metastasis [61-62].
The concept of satellite nodules was not considered in NSCLC staging system until 1992 by
the AJCC and in 1993 by the UICC [63-64].
Prior to this, all nodules were classified as M1.
The T4 descriptor includes diverse tumors with different evolution and prognosis:
• invasion of the mediastinum, heart, great vessels, trachea, esophagus, vertebral body, and
carina;
• tumor with a malignant pleural or pericardial effusion, or with satellite tumor nodule(s)
within the ipsilateral primary-tumor lobe of the lung.
The IASLC lung cancer staging project committee has acknowledged the multiple reports
showing better survival for primary tumors with satellite nodules than other T4 tumors and
this is the reason why they downstaged them accordingly [38,65].
Later studies found that the new T descriptor for satellite nodules proposed by the IASLC
reflects better the outcomes of that group of patients, which showed superior survival rates,
and now these patients are to be considered for surgery [66-67].
1.2.2.2. Pleural dissemination and pericardial effusion
According to the TNM staging manual, pleural dissemination is defined as the presence of
ipsilateral malignant pleural effusion (MPE) or pleural nodules [68]. Pleural nodules are de‐
fined as pleural tumor foci separated from direct pleural invasion by the primary tumor,
classified as T4 [69]. These pleural tumors must be differentiated from direct tumor invasion
to the visceral (T2) or parietal pleura (T3) (Table 4).
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PL category Definition T status
PL0 Tumor within the subpleural parenchyma or, invading
superficially into the pleural connective tissue below
the elastic layer.
PL0 is not a T descriptor and the T
component should be assigned on other
features.
PL1 Tumor invades beyond the elastic layer. pT2 Indicates VPI
PL2 Tumor invades to visceral pleural surface.
PL3 Tumor invades the parietal pleura. pT3
Table 4. Classification of visceral pleural invasion (VPI): Proposed modification of Hammar Classification [70]
Introduction of a new accurate definition of visceral pleural invasion (VPI); VPI is a pT2 de‐
scriptor (Table 4). The abbreviation PL is used instead of P which is also used for designa‐
tion of pTNM in distinction from cTNM. The IASLC also recommends the use of elastic
stains to distinguish between PL0 and PL1 when hematoxylin and eosin (H&E) sections are
not helpful [71].
In TNM staging,  either pleural  fluid cytology or clinical  judgment are valid to establish
the  diagnosis  of  a  MPE  and  consider  it  as  a  T4  factor  [72],  in  the  absence  of  relevant
conventional  or  guided pleural  biopsy.  Malignant  pericardial  effusions are  classified ac‐
cording to the same rules. Pleural dissemination and pericardial effusion are T4 descrip‐
tors,  grouped into stage IIIB in absence of distant metastasis.  The MPE is considered to
be a  sign of  advanced disease,  and almost  every cancer  can involve  the  pleura  [73-74].
However,  most MPE’s are due to NSCLC’s and encompass the worst  prognosis  [75-77],
even worse than in the presence of satellite nodules or mediastinal invasion; only a few
patients  survive  beyond  12  months,  regardless  of  treatment  modality,  surgery  or  not,
according  to  studies  by  Osaki  et  al.,  Sugiura  et  al.,  Mott  et  al.  and  Kameyama  et  al.
[78-81]
Ipsilateral MPE is a locally advanced disease that precludes surgical treatment in lung can‐
cer [82-83]. Unlike other malignant effusions, those caused by NSCLC have low sensitivity
to chemo- and radiotherapy [84-86]; therefore these patients are candidates for palliative
therapy. In a similar way, NSCLC is the most frequent cause of malignant pericardial effu‐
sion, which has a grim prognosis too [87-89].
The  IASLC reclassified  pleural  dissemination  from T4  to  M1a  based  on  the  magnitude
of  evidence  demonstrating  that  postoperative  survival  rates  of  patients  with  stage  IIIB
due  to  MPE  are  no  different  from  those  with  stage  IV  disease  and  significantly  lower
than in patients  with no pleural  effusion and even with non-malignant  pleural  effusion
[90-95].
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Status at thoracotomy 5-year survival (%)
No pleural effusion 45.4
Non-MPE 42.5
MPE 15.9
Pathologic stage IV 11.2
Table 5. Postoperative survival rates of NSCLC with malignant pleural effusion (MPE): no significant difference with
stage IV disease. (Data from Naruke et al [96])
1.3. Changes to N descriptors [97-98]
The accurate assessment of lymph node involvement is an important part of the manage‐
ment of lung cancer. Lymph node “maps” have been used to describe the location of nodal
metastases. However, there are discrepancies in nomenclature among maps used by Asian
and Western countries. The IASLC proposed a new lymph node map that reduces these dif‐
ferences among currently used maps, and provides precise anatomic definitions for all
lymph node stations. It has also been proposed a new method of grouping lymph node sta‐
tions together into “zones” for the sake of future survival analyses [99].
Milestones:
1. No changes were made to N descriptors. Analysis from the international database of
the IASLC showed that current N descriptors provide good survival stratification, and
therefore considered appropriate to maintain them without modifications [100].
2. New International Lymph Node Map: The IASLC has developed a new lymph node
chart to resolve disagreements in nomenclature between Naruke’s (The Japan Lung
Cancer Society) and Mountain-Dresler’s maps (American Thoracic Society). Although
the nomenclature has changed, the general concept remains the same. Patients without
nodal metastatic disease are designated as N0. Patients with N1 disease are defined as
having metastatic involvement of lymph nodes in the ipsilateral peripheral or hilar
zones. The N2 designation signifies metastatic extension to lymph nodes in the ipsilat‐
eral mediastinal (upper, aorticopulmonary, lower) or subcarinal lymph node zones. The
N3 nodal designation includes metastatic involvement of any nodes in the supraclavic‐
ular lymph node zone or nodes in contralateral mediastinal, hilar–interlobar, or periph‐
eral zone.
3. New classification of lymph nodes by grouping stations into seven “Nodal Zones” for
prognostic analysis: supraclavicular, upper, aorticopulmonary, subcarinal, lower, hilar–
interlobar, and peripheral (Table 6 and Figure 4); this proposal needs to be validated
with prospective studies and it is not yet effective in the new TNM system.
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Nodal Zone Lymph node station
Upper zone Low cervical, supraclavicular, sternal notch (1R – 1L)
Upper paratracheal (2R – 2L)
Prevascular (3a) and retrotracheal (3p)
Lower paratracheal (4R – 4L)
Aortopulmonary zone Subaortic (aortopulmonary window - 5)
Para-aortic (ascending aorta or phrenic nerve - 6)
Subcarinal zone Subcarinal (7)
Lower zone Paraesophageal (8)
Pulmonary ligament (9)
Hilar zone Hilar (10)
Interlobar superior (11s) and inferior (11i)
Peripheral zone Lobar (12)
Segmental (13)
Subsegmental (14)
Table 6. Grouping of lymph node stations into “zones”.
Survival differences were also calculated on the basis of the number of lymph node zones
involved in any single nodal designation. For instance, in pathologically staged patients
with any T and M0, those with nodal metastases to a single N1 zone had a median survival
of 52 months whereas those with metastatic spread to nodes in multiple N1 zones had a me‐
dian survival of only 31 months. Similar decreases in survival were also seen in patients
with multiple N2 nodal zone involvement (median survival 19 months) compared with
those with disease in a single N2 nodal zone (median survival 35 months) [65]. These results
showed improved survival in patients with a single N2 zone involved compared with those
with multiple N1 zones involved. These findings were validated by an external study [102],
and raising the possibility of subdividing the N1 and N2 classifications into N1a (single-
zone N1), N1b (multiple-zone N1), N2a (single-zone N2), and N2b (multiple-zone N2).
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 Figure 4. A parallel between previous Mountain-Dresler modified lymph node map originally proposed by the Ameri‐
can Thoracic Society and the proposed grouping of lymph node stations into “zones” for the purposes of prognostic
analyses from Rusch VW et al. [100].
4. Given the continuous ascension of endoscopic ultrasound techniques such as EBUS (endo‐
bronchial ultrasound) and EUS (endocopic ultrasound) guided transbronchial (TBNA) and
transesophageal (FNA) fine needle aspiration for the sampling of mediastinal lymph no‐
des, the borders between lymph node stations have been reconsidered, limiting as much as
possible the subjectivism and trying to better standardize and define nodal stations.
As Tournoy et al. showed in this graphic representation, the reach of EUS-FNA and EBUS-
TBNA is partly overlapping and partly complementary. EBUS-TBNA follows the large air‐
ways, whereas EUS-FNA is excellent for the left, posterior and lower mediastinal and
paraoesophageal stations. When both techniques are available, many of the mediastinal and
hilar lymph nodes can be reached for fine-needle aspiration. In addition, with EUS-FNA, the
left liver lobe, celiac trunk nodes, and the left adrenal gland can be assessed. With EUS,
lymph nodes can be identified if they are located in the vicinity of the esophagus. The nodes
to be identified with EUS are described in relation to vascular structures (including the aor‐
ta, the azygos vein, the left atrium, and the pulmonary artery) and the diaphragm [103-104].
With EBUS, the ultrasound window angle is much smaller, when compared with EUS (50–
60 degree angle versus 150– 180 degree angle), which makes the visualization and identifica‐
tion of large vessels or ultrasound landmarks easier with the latter (Figure 5). EUS helps in
the identification of structures and landmarks through movements of backward, forward
and rotation of the scope. In contrast to EUS, EBUS has the advantage of having a real-time
bronchoscopic view into the airways during procedures, which helps with a more accurate
identification of the lymph node stations [12].
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In general, the lymph nodes are characterized based on EBUS imaging as follows:
a. Size (in short axis): less or more than 1 cm.
b. Shape: oval or round; when the ratio of short vs. long axis of lymph nodes is smaller
than 1.5, the lymph node is defined as round; if the ratio is bigger than 1.5, it is oval.
c. Margin: indistinct or distinct; if the majority of the margin (>50%) is clearly visualized
with a high echoic border, the lymph nodes are determined as distinct. If the margin is
unclear, they are determined as indistinct.
d. Echogenecity: homogeneous or heterogeneous
e. The presence or absence of central hilar structure (CHS); CHS defined as a linear, flat,
hyperechoic area in the center of the lymph node.
f. The presence or absence of coagulation necrosis sign (CNS). CNS is a hypoechoic area
within the lymph node without blood flow. Typical coagulation necrosis sign repre‐
sents a low echoic area within the lymph node and that sometimes occupy the majority
of the lymph node. The presence of CNS had the highest specificity (92.6%) and the
highest hazard ratio (5.6) for prediction of metastatic lymph nodes [106]
Figure 5. Devices used in endoscopic and endobronchial ultrasound. Endoscopic ultrasound probe (left) and endo‐
bronchial ultrasound scope (right) [105].
Since we consider that in the light of the latest TNM classification the knowledge of lymph
node stations and their borders is of absolute importance, we will debate about it on a larger
scale in this chapter. This, according to our opinion, is going to help especially the EUS-
EBUS practitioners, since we are going to correlate from literature the schematics with CT’s
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and ultrasound in every lymph node station, in order to have a detailed mental image of the
mediastinum. (Figure 6).
Station 1 lymph nodes (Figure 7) are located caudal to the inferior margin of the cricoid but
cranial to the incisura jugularis of the sternum and cranial to the clavicles bilaterally. There‐
fore, the supraclavicular nodes are also part of station 1. The latter can be felt by a clinical
examination when enlarged; however, external ultrasound has shown to be useful for their
localization, identification, and puncture.21–24 21 [107-110].
Although the paratracheal part of station 1 can be reached by EBUS-TBNA (1R/L; bilateral–the
midline of the trachea serves as the border) or EUS-FNA (1L; left), the proposed anatomic bor‐
ders cannot be recognized with endoscopic ultrasound. Because these nodes are localized ex‐
trathoracic, an endoscopic approach is very unpractical. The endoscopes are not stable for
these very proximal stations making interpretation and sampling technically difficult and un‐
comfortable for the patient. Therefore, endoscopic ultrasound is of limited value for identifica‐
tion, delineation, and sampling of the paratracheally located station 1 nodes [21].
Figure 6. General view: CT-WLB-EBUS correlations for regional lymph nodes by IASLC system [106]
Station 2. The inferior border of station 2L is the transverse plane through the superior bor‐
der of the aortic arch. For 2R, the inferior border is then the intersection of the caudal margin
of the brachiocephalic vein with the right-sided border of the trachea. The sagittal plane tan‐
gent to the left tracheal wall now makes the difference between right and left. For endoscop‐
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ic ultrasound node identification and delineation, these revised definitions are important.
Ultrasonographic discrimination between stations 2 and 4 is evident, especially on the left
side because the apex of the aortic arch can readily be visualized by either EUS-FNA or
EBUS-TBNA. For the right-sided nodes, the margin simply follows this transverse plane,
which can serve as a surrogate for the intersection of the trachea and brachiocephalic vein
(Figure 8).
Discriminating left and right-sided nodes has clinical implications (N2 versus N3). In most
of the cases, there is no discussion about the position because the presence and the size of
the nodes as seen and measured on the CT scan also help the endoscopist in the identifica‐
tion (Figure 9). However, it can be that similarly enlarged nodes are found in this region and
that attention is needed for making the difference between N2 and N3. As a general rule, it
can be said that EUS-FNA can only reach the left paratracheal lymph node stations. With
EBUS-TBNA, both stations can be approached while no clear endoscopic or ultrasonograph‐
ic landmarks are available to discriminate left and right. Although the bronchoscopic image
helps during EBUS-TBNA, the left side of the trachea never identifies as a straight plane.
The large arteries (subclavian artery or the aortic arch) cannot help much because their posi‐
tion relative to that sagittal plane is variable. In addition, the smaller ultrasonography win‐
dow of EBUS-TBNA also makes the visualization of the anatomic ultrasound landmarks is
more limited [21].
Figure 7. Supraclavicular nodes. These include low cervical, supraclavicular and sternal notch nodes. Upper border:
lower margin of cricoid. Lower border: clavicles and upper border of manubrium. The midline of the trachea serves as
border between 1R and 1L. 2R. Right Upper Paratracheal. 2R nodes extend to the left lateral border of the trachea.
Upper border: upper border of manubrium. Lower border: intersection of caudal margin of innominate (left brachio‐
cephalic) vein with the trachea. 2L. Left Upper Paratracheal. Upper border: upper border of manubrium. Lower border:
superior border of aortic arch. [111] Courtesy of Septimiu Murgu, MD and Henri Colt,MD; Bronchoscopy International
www.bronchoscopy.org
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Figure 8. Station 2 visualized by EBUS at the 5th tracheal ring [106]. Courtesy of Septimiu Murgu, MD and Henri
Colt,MD; Bronchoscopy International www.bronchoscopy.org
Figure 9. Station 2 node in front of the trachea, i.e. a 2R-node. There is also a small prevascular node, i.e. a station 3A
node.
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Station 3 lymph nodes are defined with an anterior part being the prevascular nodes and a
posterior part being the retrotracheal nodes. The craniocaudal extent goes for both from the
sternal notch down to the main carina. Although the prevascular station 3A can be visual‐
ized with EBUS as lying ventrally from the large vessels, there are no anatomic ultrasound
landmarks to recognize the superior border of this lymph node station. Sampling station 3A
by endoscopic ultrasound is impossible because of the interposition of the large vessels. This
contrasts with station 3P, which is situated in between the pars membranacea of the trachea
and the vertebrae (Figure 11). It can be seen and sampled by both EUS-FNA and EBUS-
TBNA. Although there is no ultrasound landmark for the superior margin of 3P either the
inferior margin being the main carina level corresponds with the level of the main stem or
left pulmonary artery during EUS and can be seen as an anatomic structure during EBUS.
The margin between 3P and 2/4L is the left posterior tracheal corner, which is identifiable by
EUS-FNA or EBUS-TBNA. The margin between 3P and 2/4R is the right posterior tracheal
corner that can be identified during EBUS-TBNA.
Station 4 lymph nodes are located paratracheally but situated caudal to the transverse aortic
arch plane (Figure 12). The sagittal plane on the left side of the trachea is the margin be‐
tween left and right, just like in station 2 nodes. By consequence, EUS-FNA in general can‐
not approach a right paratracheal node. The comments made to discriminate between 4R
and 4L with EBUS-TBNA are identical to those for stations 2. However, what can be helpful
for the endoscopist is that 4R nodes are situated posterior to the superior vena cava and/or
ascending aorta, both presenting as large vessels with a vertical course, which can be readily
visualized by EBUS-TBNA. The inferior margins of station 4 nodes have been redefined
with important clinical implications, also for endoscopic ultrasound. The pleural reflection
no longer serves as the border between stations 4 and 10. Station 4L has now an inferior bor‐
der defined by the superior rim of the left main pulmonary artery and a lateral margin de‐
fined by the aortopulmonary ligament (Figures 12 – 14). With both EUS-FNA and EBUS-
TBNA, the cranial rim of the left main pulmonary artery can be visualized. The
aortopulmonary ligament is invisible for ultrasound. Station 4R’s inferior border has now
been redefined as the inferior border of the azygos vein. This new definition is better be‐
cause the anatomic margin being the pleural fold is invisible for conventional or endoscopic
imaging, whereas the azygos vein is always visible. During EBUS-TBNA, it typically
presents in the right tracheobronchial corner as a kidney-shaped vessel (Figures 12, 13). By
consequence, EBUS-TBNA now can be used more confidently to discriminate between me‐
diastinal 4R and hilar 10R nodes. The 4R nodes are by consequence characterized by their
position just dorsally from the superior caval vein and/or aorta and medially but not distally
to the azygos vein.
4R. Right Lower Paratracheal
• Upper border: intersection of caudal margin of innominate (left brachiocephalic) vein
with the trachea.
• Lower border:lower border of azygos vein.
4R nodes extend to the left lateral border of the trachea.
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4L. Left Lower Paratracheal
4L nodes are lower paratracheal nodes that are located to the left of the left tracheal border,
between a horizontal line drawn tangentially to the upper margin of the aortic arch and a
line extending across the left main bronchus at the level of the upper margin of the left up‐
per lobe bronchus. These include paratracheal nodes that are located medially to the liga‐
mentum arteriosum.
Station 5 (AP-window) nodes are located laterally to the ligamentum arteriosum [111].
Figure 10. Prevascular and Prevertabral nodes. Station 3 nodes are not adjacent to the trachea like station 2 nodes.
They are either: 3A anterior to the vessels or 3P behind the esophagus, which lies prevertebrally. Station 3 nodes are
not accessible with mediastinoscopy. 3P nodes can be accessible with endoscopic ultrasound (EUS) [111].
 
Figure 11. Lymph nodes station 4 and their borders
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Figure 12. Sagital CT, bronchoscopic image and EBUS image of station 4R and 4L lymph node stations [106]. Courtesy
of Septimiu Murgu, MD and Henri Colt,MD; Bronchoscopy International www.bronchoscopy.org
Figure 13. Examples of mediastinal lymph nodes and their anatomic relations with described borders [111].
Station 5 lymph nodes are situated laterally to station 4L nodes with the ligamentum arte‐
riosum as anatomic border (Figures 11, 13). The inferior edge is similar for both, whereas the
cranial edge is not. Although 4L nodes are situated caudal to the superior border of the aort‐
ic arch, station 5 nodes are located caudal to the inferior border of the aortic arch (Figure 19).
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Because the ligamentum arteriosum cannot be discerned by means of ultrasound, the differ‐
entiation between 4L and 5 can be difficult, especially when both stations contain suspect
lymph nodes. Station 5 nodes can be identified by EUS-FNA and EBUS-TBNA although the
latter is often more demanding. Because of the interposition of aortic arch or pulmonary ar‐
tery, station 5 can only be punctured in selected patients with enlarged nodes.
Station 6 mediastinal lymph nodes are located lateral to the ascending aorta and aortic arch,
in between the transverse planes at the superior and inferior border of the aortic arch. (Fig‐
ures 13, 14) These nodes can most often be identified by means of EUS-FNA, whereas this is
not always possible with EBUS-TBNA. The nodes in station 6 can only be punctured by a
transaortal approach, but extended mediastinoscopy is advised instead [21, 112].
Figure 14. Lymph nodes stations 5 and 6 and their relation with the great vessels [111].
Station 5. Subaortic nodes: Subaortic or aorto-pulmonary window nodes are lateral to the
ligamentum arteriosum or the aorta or left pulmonary artery and proximal to the first
branch of the left pulmonary artery and lie within the mediastinal pleural envelope.
Station 6. Para-aortic nodes: Para-aortic (ascending aorta or phrenic) nodes are located ante‐
riorly and laterally to the ascending aorta and the aortic arch from the upper margin to the
lower margin of the aortic arch [111].
Station 7 lymph nodes have an inferior border that is redefined. (Figure 15).On the left side,
this is the superior border of the lower lobe bronchus, and on the right side, this is the inferi‐
or border of the intermediate bronchus. (Figure 16) The lymph nodes in this station can be
seen and biopsied by both EUS-FNA and EBUS-TBNA. Formerly, an anterior and posterior
part of this node was recognized. This was meaningful because a cervical mediastinoscopy
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cannot reach the posterior part of this station. With EUS-FNA and EBUS-TBNA, the entire
subcarinal area can be approached. Although identification of the nodes in this station is
easy for both EUS-FNA (the nodes lay just dorsally to the origin of the left pulmonary artery
and cranial to the left atrium) and EBUS-TBNA (by means of the endoscopic view), the de‐
lineation of the inferior border by means of endoscopic ultrasound is, however, not easy.
With EUS-FNA, the left atrium is generally seen as the anatomic border above which the
subcarinal nodes are situated, although this is with the new definition probably too restric‐
tive. The relation of the left atrium or pulmonary artery to the bronchus intermedius and the
left lower lobe bronchus, the latter being the newly defined inferior borders of station 7, can
be variable. With EBUS-TBNA, the delineation of the inferior border is possible because this
investigation allows a simultaneous bronchoscopic view of the bronchial tree although there
are no distinct corresponding ultrasound landmarks.
Figure 15. Virtual borders between lymph node stations and their relation with the great vessels of mediastinum
[113].
Figure 16. The subcarinal station shown on CT scan (left panel) can easily be visualized with both EUS (right panel) but
of course also with EBUS. During EUS, the subcarinal station identifies as a round, hypoechogenic sharply edged struc‐
ture located in between the esophagus and the pulmonary artery. The upper rim of this artery corresponds in general
with the main carina and is helpful during EUS. The main carina is visualized by means of endoscopy during EBUS. The
inferior border is the roof of the lower lobe bronchus on the left and the bottom of the bronchus intermedius on the
right. There are no unique ultrasound features that correspond to this definition although endoscopy during EBUS is
helpful [21]. Courtesy of Septimiu Murgu, MD and Henri Colt,MD; Bronchoscopy International www.bronchoscopy.org
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Stations 8 and 9 are the paraoesophageal and pulmonary ligament nodes, respectively, and
are situated inferior to the inferior margins of station 7 lymph nodes. The superior border of
these lymph nodes is as such defined by the inferior margin of the subcarinal area. Station 8
nodes are located along the left atrium (Figures 17, 18), whereas station 9 nodes are lying
within the pulmonary ligament (Figure 19). Although the latter is a structure that cannot be
seen with endoscopic ultrasound, station 9 nodes are located just cranial to the diaphragm,
which is readily identifiable with EUS-FNA. Stations 8 and 9 lymph nodes can be thus ap‐
proached by means of EUS-FNA. Occasionally, station 8 nodes can be found by EBUS-
TBNA. However, and as suggested above, one has to take into account the inferior stretch of
the subcarinal nodes making this station in addition to station 9 becomes invisible for EBUS-
TBNA. When performing EUS-FNA, one cannot confuse a lesion or lymph node with the
esophagus. When performing EBUSTBNA, the esophagus can be seen as a multilayered
structure with a hyperechogenic line in the middle corresponding with air not to be misin‐
terpreted as a lymph node. The discrimination between the left- and right-sided nodes is the
midline. Although no formal ultrasound characteristics for the midline are available, the rel‐
ative position of the endoscope to the descending aorta can help.
 
Figure 17. Station 8 Paraesophageal nodes: these nodes are below the carinal nodes and extend caudally to the dia‐
fragm. On the left an image below the carina. To the right of the esophagus a station 8 node [111].
 
Figure 18. Station 9. Pulmonary ligament nodes: pulmonary ligament nodes are lying within the pulmonary ligament,
including those in the posterior wall and lower part of the inferior pulmonary vein. The pulmonary ligament is the
inferior extension of the mediastinal pleural reflections that surround the hila [111].
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Figure 19. Hilar nodes Hilar nodes are proximal lobar nodes, distal to the mediastinal pleural reflection and nodes
adjacent to the intermediate bronchus on the right. Nodes in station 10 - 14 are all N1-nodes, since they are not locat‐
ed in the mediastinum [111].
Station 10 or hilar lymph nodes are situated immediately adjacent to the main stem bron‐
chus but caudal to the inferior border of azygos vein on the right and superior rim pulmona‐
ry veins and artery on the left. These nodes can be seen and sampled by EBUS-TBNA
(Figures 20, 21). The inferior margin of station 10R is the interlobar region. There is no
unique ultrasound feature that defines that border, but because a bronchoscopic view is
available during EBUS-TBNA, the secondary carina or the upper lobe split off can serve as
surrogate here. EUS-FNA has been thought to be unable to see and sample hilar stations.
However, there is no doubt that in certain cases, station 10 nodes located medially from the
main stem bronchi can be assessed. Endoscopists should be aware of this because misinter‐
pretation could lead to overstaging [114].
 
Figure 20. Station 10 lymph nodes: sagittal CT, endobronchial view and corresponding EBUS [106]. Courtesy of Septi‐
miu Murgu, MD and Henri Colt,MD; Bronchoscopy International www.bronchoscopy.org
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Once the secondary carina is reached, station 11 lymph nodes (or interlobar nodes) are en‐
countered. From this station on, the nodes can only be approached by EBUS-TBNA and not
by EUS-FNA. These nodes are located just underneath the mucosa of the secondary carina
on the left. There is a division between 11s and 11i on the right side. The former indicate the
nodes between upper lobe and intermediate bronchus, the latter are situated in between
middle and lower lobe ultrasound landmarks are not available; however, the synchronous
endoscopic view enables the identification of the relevant lobe split offs.
 
Figure 21. Station 11 lymph nodes (hilar nodes): Sagittal CT, endoscopic view and corresponding EBUS [106]. Courte‐
sy of Septimiu Murgu, MD and Henri Colt,MD; Bronchoscopy International www.bronchoscopy.org
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Once the lobar bronchi originate, then station 12 is reached. Again, there are no unique ul‐
trasound borders, only the endoscopic view can help for guidance. Stations 13 and 14 are
segmental and subsegmental nodes. Frequently, the EBUS-TBNA endoscope is too large to
approach the segments and subsegments and their lymph nodes.
In closing, the new IASLC map maintains the lymph node stations of the other maps, but it
also groups those that are anatomically proximal in lymph node areas in order to make the
lymph node classification easier, especially in patients who will not undergo surgery. In this
map, all the lymph node stations are defined by anatomically precise limits that are easy to
recognize with imaging techniques and inspection during invasive explorations or thoracot‐
omy. The innovations of this lymph node map are:
• The creation of a supraclavicular lymph node area that includes the supraclavicular, low‐
er cervical (caudal on the lower edge of the cricoid cartilage) and the suprasternal fossa
lymph nodes. If these lymph nodes are invaded by a tumor, they are classified as N3, re‐
gardless of the side of the tumor.
• The widening of the subcarinal lymph node station. It now includes all the lymph nodes
from the tracheal bifurcation until the upper edge of the lower left lobar bronchus and the
lower edge of the intermediary bronchus. If they are affected by tumors, these lymph no‐
des are classified as N2. This new subcarinal station includes lymph nodes that before, at
least according to the Japanese map, were hilar (adjacent to the lower sides of the main
bronchi), that could be classified as N1 or N3, depending on the side of the tumor. The
larger size of this subcarinal station will mean an increase in N2 tumors in detriment of
N1 and N3 tumors.
• The incorporation of precise limits for station number 10, the hilar station, which facili‐
tates the prospective collection of data in order to clarify the prognostic role of this sta‐
tion, whose placement on other maps has always been controversial.
• The shift in the midline of the upper mediastinum from the tracheal anatomical midline
to the left paratracheal margin exclusively affects the upper and lower right and left para‐
tracheal stations. This modification implies that the affected lymph nodes that are to the
left of the anatomical midline, but to the right of the new left paratracheal line, will be N2
for tumors of the right lung, but N3 for those of the left lung.
1.4. Changes to M descriptors [25, 39]
The patients with lung cancer studied for the 7th edition of the TNM Classification of Malig‐
nant Tumors presented the following survival rates at 1 and 5 years: T4 any N M0, 53% and
16%; pleural dissemination, 45% and 6%; contralateral pulmonary nodule(s), 46% and 3%,
and distant metastasis, 22% and 1%; in this latter case, with significantly lower survival rates
than previously cited [39]. With such references, it was decided to subdivide the M compo‐
nent into M1a (presence of pleural dissemination or contralateral pulmonary nodule(s)) and
M1b (distant metastasis).
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Subclassify the M1 component in (Table 7):
• M1a: Intrathoracic metastasis.
• M1b: Extrathoracic (distant) metastasis.
• Reclassify pleural dissemination (malignant pleural effusions, pleural nodules) and ma‐
lignant pericardial effusions as a metastasis descriptor: from T4 to M1a.
• Subclassify M1 by additional nodules in the contralateral lung as M1a.
• Subclassify M1 by distant metastases as M1b.
• The MX and pM0 designation has been eliminated from the AJCC/UICC TNM system.
M factor definitions 6th ed descriptor 7th ed descriptor
Metastasis cannot be assessed. MX M0
Malignant pericardial effusion. T4 M1a
Pleural dissemination (malignant pleural effusions, pleural
nodules). T4 M1a
Additional nodules in the contralateral lung (same histology). M1 M1a
Distant metastasis. M1 M1b
Table 7. M descriptor changes: comparison between 6th and 7th edition of the TNM Classification of Malignant
Tumors [39].
1.4.1. Additional changes
• Introduction of a new accurate definition of visceral pleural invasion (VPI); VPI is a pT2
descriptor (Table 8). To avoid confusion, the abbreviation PL is employed instead of P
which is also used for designation of pTNM in distinction from cTNM. The IASLC also
recommends the use of elastic stains to distinguish between PL0 and PL1 when hematox‐
ylin and eosin (H&E) sections are not helpful [71].
PL category Definition T status
PL0 Tumor within the subpleural parenchyma or, invading
superficially into the pleural connective tissue below
the elastic layer.
PL0 is not a T descriptor and the T
component should be assigned on other
features.
PL1 Tumor invades beyond the elastic layer. pT2 Indicates VPI
PL2 Tumor invades to visceral pleural surface.
PL3 Tumor invades the parietal pleura. pT3
Table 8. Classification of visceral pleural invasion (VPI): Proposed modification of Hammar Classification [115]
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• Clinical TNM staging now is valid for SCLC, and stratification by stage I to III should be
included in clinical trials of early stage disease [116].
• Pathologic TNM staging must be used for all SCLC cases [117]..The International Staging
Committee of the IASLC has confirmed that the survival of patients with SCLC worsened
as the T and N categories increased [116]. It was also observed that, except in stage IIA,
which had only 55 patients for analysis, the 5-year survival worsened as the stage pro‐
gressed: IA, 38%; IB, 21%; IIA, 38%; IIB, 18%; IIIA, 13%; IIIB, 9%, and IV, 1%. Based on
this, the proposal to use the TNM system for staging SCLC was confirmed.
• Carcinoid tumors are now included within the TNM classification [118], a new staging sys‐
tem for neuroendocrine tumors. Lung carcinoids are staged in the same way as carcinomas.
Even though the 6th TNM classification specified that it was not applicable to carcinoid tu‐
mors, several studies have used it, finding prognostic differences among the stages. The
IASLC has also confirmed that those classified as stage I lived significantly more than those
in stage II, and these significantly more than those in stages III–IV; therefore, the new TNM
classification of 2009 is recommended to describe the extension of these tumors [118].
Knowing the previous arguments for reorganizing some sections of the T and M components, a
sophisticated statistical study was carried out with 17,726 patients whose tumors were better
staged [119]. The different survival curves for each stage were obtained, which, without over‐
lapping among them, presented worse levels as the tumor extension increased. This confirms
the new stage grouping (Table 9), whose 5-year survivals for each stage were, according to clin‐
ical and pathological staging, respectively, the following: IA, 50% and 73%; IB, 43% and 58%;
IIA, 36% and 46%; IIB, 25% and 36%; IIIA, 19% and 24%; IIIB, 7% and 9%, and IV, 2% and 13%.
6th ed 7th ed
N0 N1 N2 N3
T/M descriptors
T1 (=2cm) T1a IA IIA IIIA IIIB
T1 (>2 cm =3 cm) T1b IA IIA IIIA IIIB
T2 (>3 cm =5 cm) T2a IB IIA(IIB) IIIA IIIB
T2 (>5 cm = 7 cm) T2b IIA IIB IIIA IIIB
T2 (>7 cm)
T3
IIB(IB) IIIA(IIB) IIIA IIIB
T3 (direct invasion) IIB IIIA IIIA IIIB
T4 (same lobe nodules) IIIB(IIIA) IIIA(IIIB) IIIA(IIIB) IIIB
T4 (extension) T4 IIIA(IIIB) IIIA(IIIB) IIIB IIIBM1 (ipsilateral nodules) IIIA(IV) IIIA(IV) IIIB(IV) IIIB(IV)
T4 (pleural or pericardial effusion) M1a IV(IIIB) IV(IIIB) IV(IIIB) IV(IIIB)M1 (contralateral nodules) IV IV IV IV
M1 (distant) M1b IV IV IV IV
Table 9. Stage Grouping Comparisons: Sixth Edition Versus Seventh Edition Descriptors, T and M Categories, and
Stage Groupings.
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Cells in bold indicate a change in the stage from the sixth edition. Adjacent stage in paren‐
theses represents staging from the sixth edition. T = primary tumor; N0 = no regional lymph
node metastasis; N1 = metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph
nodes and intrapulmonary nodes, including involvement by direct extension; N2 = metasta‐
sis in ipsilateral mediastinal and/or subcarinal lymph node(s); N3 = metastasis in contrala‐
teral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular
lymph node(s); M = distant metastasis [65].
Stage groupings were modified due to changes to the TNM descriptors (Table 5).
1. TNM grouping categories that were down-staged:
a. T2 smaller tumors, now T2a (>3 cm =5 cm), N1M0 are down-staged from IIB to IIA.
b. T4 tumors due to additional nodules in primary lobe, now T3, are down-staged
from IIIB to IIB (N0) or to IIIA (N1-2).
c. M1 cases due to additional nodules in other ipsilateral lobe(s), now T4, are down-
staged from IV to IIIB (N2-3) or to IIIA (N0-1).
d. T4 tumors due to other factors, N0-1 are down-staged from IIIB to IIIA.
2. TNM grouping categories that were up-staged:
a. T2 larger tumors, now T2b (>5 cm =7 cm), N0M0 are up-staged from IB to IIA.
b. T2 tumors >7 cm, now T3, are up-staged: T3N0M0 from IB to IIB and T3N1M0 from
IIB to IIIA.
c. Tumors with pleural nodules or malignant pleural (or pericardial) effusion were re‐
classified from T4 to M1a, therefore are up-staged from stage IIIB to IV [120].
The main limitations are derived from the retrospective character of some databases that
were not designed to study the TNM classification and lack precise anatomical details about
the tumor extension, the number and lymph node stations affected or the differences be‐
tween the different forms of M1 disease. For this reason, the IASLC itself has initiated a pro‐
spective project aimed at once again updating the TNM classification in 2016, validating all
the T, N and M descriptors, especially those who have not been until now. Thus, a large in‐
ternational database is being constituted that, correcting the geographical omissions and dis‐
proportions in the therapeutic modalities, includes patients with non-small-cell tumors,
small-cell tumors and their neuroendocrine subtypes.
In conclusion, the IASLC staging classification is unquestionably a major advance. The size
of the database, the broad international spectrum, the careful and detailed analysis, as well
as the internal and external validation, are tremendous achievements and relatively unique
among types of cancer [121].
So, the main advantages of the new classification would be:
• The size of the database, the largest ever collected for any cancer type.
• For the first time, data was collected from different countries.
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• The timeframe of 10 years allowed for 5 years follow-up.
• Cases included all treatment modalities.
• Pathologic and clinical staging where considered in survival analysis.
• The statistical analysis included meticulous internal and external validation.
• Changes to the TNM descriptors and stage groups were derived strictly from the outcome
measure of overall survival.
The new TNM system is less intuitive and more complex than the 6th edition, and will be
more difficult to learn. The oncology community needs to overcome the higher learning
curve in order to offer patients the most appropriate treatment choices based on more accu‐
rate prognostic information [120].
2. Electromagnetic navigation bronchoscopy
It is known that diagnostic yield of flexible bronchoscopy is limited by its inability to guide
biopsy instruments directly to the lesion. As it was expected, diagnosis success rate is de‐
pendent on the size and location of the lesion. The diagnostic yield of flexible bronchoscopy
is expected to be between 20 and 84%. However, current nonsurgical techniques available to
diagnose small peripheral lung lesions (SPLL) are limited either by low accuracy [122–125]
or by potential complications [126–129].
For lesions less than 2 cm in diameter, the diagnostic yield of flexible bronchoscopy is 14%
for peripheral lesions in the outer third of the chest and as high as 31% if in the proximal
two-thirds [130]. The diagnostic yield of flexible bronchoscopy for mediastinal lymph nodes
using transbronchial needle aspiration (TBNA) is reported to be between 15 and 83% [131].
Also, diagnostic yield of TBNA in staging of bronchogenic carcinoma is reported to be be‐
tween 50 and 60% [132].
Within the past several years, electromagnetic navigation guided bronchoscopy (EGB) has
proven very effective at assessing pulmonary nodules accurately with very low complica‐
tion rates. EGB consists of four elements:
1. Computer software that utilizes thin-slice CT to create a three-dimensional rendering of
the lung and tracheobronchial tree, which can then be used for virtual bronchoscopy.
2. A sensor probe that fits through the small working/suction channel of a bronchoscope
with a steering mechanism. Because the sensor probe is recognizable within the electro‐
magnetic field, it can be navigated through the small airways of the lung toward pe‐
ripheral lesions not reachable by conventional bronchoscopy (Figure 22).
3. An electromagnetic field encompassing the patient’s thorax, so that the real anatomy
can be merged with the computer generated (virtual) anatomy by use of standard “reg‐
istration points” (e.g., carina, takeoff of the right upper lobe bronchus, bifurcation be‐
tween the left upper and lower lobes).
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4. A hollow, extended working channel (EWC) that can be secured in a small peripheral
airway and used to pass diagnostic instruments such as brushes, aspirating needles and
biopsy forceps [133].
The ideal patient for EGB should be one with peripheral pulmonary lesion (solid or fatty sol‐
id nodule located beyond the visible range of flexible bronchoscopy) detected by chest radi‐
ography and CT or presenting with suspicion of cancer by CT morphology or positive
positron emission tomography (PET) scan, as well as with a nondiagnostic conventional
bronchoscopy in most of these cases; he should have absence of other metastatic lesions ac‐
cessible for biopsy, a negative TTNA or contraindication for TTNA (severe pulmonary im‐
pairment, bleeding diathesis, lesions not accessible by TTNA as judged by a radiologist
panel) and contraindication for straightforward curative surgery; in case of associated me‐
diastinal lymph nodes should have a negative transbronchial needle aspiration (TBNA) or
difficult to reach with TBNA lymph nodes.
Those patients who should not undergo EGB are those with contraindication to short-acting
anesthetic agents, bleeding diathesis, presence of concomitant endobronchial lesion, pres‐
ence of a pacemaker/defibrillator or a diagnosis by other means (sputum cytology, microbi‐
ology) that offers a reliable and easy to control course of treatment.
Navigation aim is to closely approach the target lesion (distance between sensor tip and le‐
sion centre ≤15 mm) and take as many biopsies as possible for each lesion. At every three
attempts is advised that the forceps should be withdrawn and the position of the sensor
probe in relation to the target lesion checked.
Makris D et al. also recommends that all patients should undertake a CT scan prior to EGB
with the following technical criteria: slice thickness 2–3.5 mm, interval between slices (with
overlap of 1 mm) 1-2.5 mm, image size 512x512 pixels and dicom format [134].
As for anesthesia, Gildea TR et al. considers that all procedures (flexible bronchoscopy,
bronchial washings, bronchoalveolar lavage and the actual EGB) can be safely performed
using conscious sedation with intravenous 2 mg boluses of both midazolam and morphine
with topical lidocaine [135].
In an emblematic study from Gildea TR et al. in 2006, the role of electromagnetic navigation
bronchoscopy using super-Dimension/Bronchus System as a novel method to increase diag‐
nostic yield of peripheral and mediastinal lung lesions was investigated. The superDimen‐
sion/bronchus system is an image-guided localization system, which is designed to guide
bronchoscopic tools to predetermined points within the bronchial tree. The device uses three
separate technologies that are combined to enable navigation of dedicated tools within the
lung in real time.
The first component is the planning software, which converts digital imaging and communi‐
cations in medicine standards (DICOM) images from a computed tomography (CT) scan in‐
to multiplanar images with three-dimensional reconstruction and virtual bronchoscopy of
the airways.
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The second component is a steerable probe that contains a position sensor attached to an eight-
way steerable instrument that has the ability to navigate turns in the endobronchial tree [135].
Figure 22. The steerable probe (SP) with bronchoscope [18].
The third component is an electromagnetic (EM) board, which is a field generator connected
to a computer containing the planning data. The exact position of the steerable probe when
placed within the EM field is depicted on the system monitor.
Registration is the process by which the computer links the five to six virtual fiducial mark‐
ers to the actual position in the patient. Upon registration completion, the average fiducial
target registration error (AFTRE) score was given in millimetres (mm). The AFTRE is the ra‐
dius of expected difference of the location of the tip of the steerable probe in the actual pa‐
tient compared with where it is expected to be in the virtual patient [135].
After registration, navigation is performed with simultaneous advancement of the steerable
probe toward the target and directing steerable probe to the lesion. The closest distance be‐
tween the steerable probe tip and the lesion centre is recorded. When navigation is complet‐
ed, the steerable probe is removed, leaving the extendable working channel through which
brushings and TBBXs or TBNA were performed [135].
In this study, biopsies were performed using a C-arm fluoroscopy unit. All instruments
were visualized under fluoroscopy only after navigation was completed to confirm proper
function and position of the bronchoscopic tools relative to the lesion and the pleura. Brush
biopsies involved two to three passes, and four pieces of tissue were obtained by TBBX.
TBNA usually was done with 2 to 4 passes of a combination of 19-G and 22-G needles de‐
pending on physician choice [130, 135-139].
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Eberhardt et al. [18] reported in 2007 92 peripheral lung lesions biopsies from 89 consecutive
subjects. The diagnostic yield of EGB was 67%, which was independent of lesion size. Total
procedure time ranged from 16.3 to 45.0 min (mean [± SD] procedure time, 26.9 ± 6.5 min).
The mean navigation error was 9 ± 6 mm(range, 1 to 31 mm). They reported two incidences
of pneumothorax for which no intervention was required. When analyzed by lobar distribu‐
tion, there was a trend toward a higher ENB yield in diagnosing lesions in the right middle
lobe (88%). They concluded that EGB can be used as an independent bronchoscopic techni‐
que without the need for fluoroscopy when compared with other available studies. There
was no increased risk of pneumothorax (2 of 89 patients; 2%). The upper lobes tend to have
sharper angles in the bronchial tree that may be challenging to navigate even with a steera‐
ble sensor probe. The EWC ends close to the tip of the sensor probe and makes it less flexi‐
ble. This reduces the range of deflection and, consequently, the ability to navigate. It can
also make the probe flip into a different position when negotiating some tight angles in the
bronchi. Navigation in the lower lobes is more affected by diaphragmatic movement during
breathing and could result in larger errors than recorded. This is because the planning data
are based on CT scan images acquired in a single breathhold [140, 141].
Eberhardt et al. also showed that the improved yield of EGB compared to conventional
transbronchial lung biopsy in small lesions (diameter ≤ 2 cm) can be attributed to the im‐
proved precision in navigation. This study has shown the yield, safety, and timesaving with
use of the EGB system without the need for fluoroscopy. This system eliminates radiation
exposure and could reduce procedure costs. The diagnostic utility of the use of EGB in the
biopsy of peripheral lung lesions appears to be equivalent to other advanced techniques like
endobronchial ultrasound [142-144].
Apparently, these techniques have pushed bronchoscopic biopsy yields closer to those ach‐
ieved by CT scan-guided transthoracic needle biopsy and surgery. Given the relative com‐
fort [145] and safety [146] of flexible bronchoscopy, and the recognized risks of both CT
scan-guided [147-149] and surgical biopsies [150], there is growing need to develop and re‐
fine these techniques. The expanded role of lung cancer screening, in which the vast majori‐
ty of lesions is benign, makes this all the more important [151]. Multimodality diagnosis by
combining ENB with other bronchoscopic and imaging techniques may further enhance the
diagnostic yield [140].
3. Autoflorescence Bronchoscopy (AFB)
Visible light perceived by the human eye comprises the whole wavelength range, between
400–700 nm. Conventional bronchoscopy illuminates mucosal structures of the airwaves
with the full wave spectrum; therefore, light gets reflected, backscattered or absorbed by the
structures it encounters, thus providing the human eye with an image [152]. Tissues show a
natural autoflorescence when excited in the 200-460 nm range; however, only the visible
part of this range is used in medical applications [153].
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However, the light source attached to the bronchoscope can emit only blue light, as a pro‐
portion of the blue spectrum excites the cellular chromophores, such as collagen, elastin or
keratin, contained in the layers of the submucosa, especially within the connective tissue
comprised in the elastic fiber bundles, or on the exterior surface of the cartilages (perichon‐
drium). When excited by blue-violet light in the 400-450 nm spectrum, the excited chromo‐
phores of normal cellular lines found in the mucosa display a green tint. Another aspect of
the autoflorescence theory refers to the thickness and cellular morphology of the examined
tissue. Tumors and premalignant lesions have an increased mucosal thickness and therefore
absorb more of the excitation occurring from fluorescence light, in what is called “the archi‐
tectural effect” [153, 154]. Tissues that underwent a morphological change due to various
pathological conditions, predominantly premalignant dysplasia or metaplasia-like phenom‐
enon, are colored differently as the green fluorescence is affected by either alterations of cel‐
lular chemistry, morphology or epithelial thickness [155–157]. A wide range of AFB devices
are currently available on the market: the Storz D-light system [158], Pentax SAFE-1000
[159], the Xilix LIFE system [158] or the DAFE system by Richard Wolf [160].
The main advantage of AFB is that progressive dysplasia of the mucosal layers also results
in a progressive transition from normal green autoflorescence to a red-brown color, specific
to precancerous or malignant lesions. This makes early premalignant lesions far easier to
spot during bronchoscopy as compared to regular white-light based techniques. Inflamma‐
tory reactions, granulomas, scars, dysplasia/metaplasia and early malignant lesions which
are hard to spot due to their submucosal confinement are therefore easily spotted due to
their dark red-brown appearance, surrounded by normal green tissue [155–157].
The addition of AFB to conventional endoscopy can significantly increase diagnostic rate of
early malignant or premalignant lesion, without the need of tumor sensitizers and therefore
with no additional complications to standard bronchoscopy techniques. The detection rate
of high-grade dysplasia and carcinoma in-situ (CIS) is increased to 88% after using AFB, up
from the median 40% detection rate that conventional white-light bronchoscopy provides
[161, 162]. However, as already stated, both premalignant lesions and various inflammatory
conditions have similar appearances in AFB. Therefore, the specificity is rather low, with a
high rate of false positive investigations [163, 164].
Since diffuse reflectance spectroscopy measures directly the changes in the path of white
light through tissue scattering and absorption levels, some have theorized that combining
autofluorescence with diffuse reflectance probes may enhance the specificity of this method.
Preliminary findings have shown that a combination between the two can significantly im‐
prove the positive predictive value of AFB without altering the already attained high sensi‐
tivity for premalignant and early malignant lesions [165] (Bard MPL et al, 2005). Other
attempts to improve specificity by local spectroscopical measurements have shown promis‐
ing results, making way for one-stop techniques which would combine two types of wave‐
length measurement and fluorophore weighting [153, 165].
One study investigated the use of AFB in primary lung cancer, after treatment of head and
neck cancer, detecting 29% (12/44 patients) of all second primary lung cancers, while detect‐
ing early lesions in two patients which would otherwise be missed by conventional imaging
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methods [166]. Early reports of Lam and his team in asbestos and diesel-exposed individu‐
als showed an 86% sensitivity for moderate to severe dysplasia and CIS in the case of AFB,
compared to just 52% for white light bronchoscopy [167]. A multicenter study performed by
Lam in 1998 with the LIFE system, on 173 patients (142 biopsy-proven cases of severe dys‐
plasia, CIS or invasive cancer) showed that AFB has a relative sensitivity of 2.71 compared
to conventional bronchoscopy, successfully detecting 91 cases in comparison to only 35 with
bronchoscopy alone. When considering intraepithelial lesions alone, the relative sensitivity
increases to 6.1 for AFB compared to standard bronchoscopy [164].
A correlation between the loss of fluorescence and the grade of dysplasia; therefore, a
trained endoscopist can differentiate these gradations to some extent, being even able to
identify inflammatory or granulomatous lesions [155]. This would In turn greatly improve
the specificity of AFB. A different approach consists in the usage of computer assisted analy‐
sis of signals of different wavelengths, represented in a spectrogram which in turn can clas‐
sify benign from malignant lesions.
4. Narrow-Band Imaging (NBI)
NBI is a novel imaging technique capable of improving the visualization of superficial struc‐
tures of the respiratory mucosa [168, 169]. NBI is used for an accurate classification of le‐
sions, even though it does not have an established role during routine bronchoscopy [170–
172]. High magnification bronchoscopy in combination with NBI can visualize the altered
micro-vascularization which is formed in dysplastic or neoplastic lesions [173]. As the tumor
progresses, it requires an adequately enlarged blood supply, therefore in most cancers, in‐
cluding those of the lungs and airways, neo angiogenesis is a constant phenomenon through
which newly formed vessels are constantly produced in order to supplement local needs.
These vessels form irregular aberrant patterns, having unequal diameters, tortuous configu‐
rations and uneven segment lengths.
The principle of NBI is simple: three optical filters segment the RGB (red-green-blue) light
spectrum in sequence, thus narrowing the bandwidth of the spectral transmittance [174].
This allows for visual marking of capillary structures of the sub-mucosa in deep red color,
allowing an easier identification and characterization, as different wavelengths penetrate the
tissue at different depths. The filtering system is placed in the optical illumination system
and basically contains two narrow wavelength components: NBI-B corresponding to the
400-430 nm range (blue and green visualization) and NBI-G for the 530-550 nm range (red
visualization), while a third filter can be installed for an accurate segmentation of the blue-
green features, operating in the 430-460 nm range; the optical light-source usually operates
in the 400-700 nm wavelength range. All current models include a 2-filter system, which em‐
phasizes capillaries in the superficial mucosal layers by the 400-430 nm light, coloring them
in shades of brown, while deeper mucosal or submucosal vessels are displayed in cyan by
using the 530-550 nm filter. Modern systems allow for easy switch between the normal WLI
and the enhanced NBI operations [168].
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Limitations of the technology arise from the fact that not all lung malignancies develop sub‐
mucosal neo vascularization visible from the airways, therefore potential false-negative NBI
findings can be frequent when used in combination with WLB. Its sensitivity may be how‐
ever increased when used in conjunction with other specific techniques such as AFB; how‐
ever, its role in the screening process for lung malignancies is yet to be determined. A step
further in this direction would be the standardization of imaging findings, based on clinical
descriptions and classification of abnormal airway vascularity. High magnification broncho‐
scopy can improve the specificity of the technique, as it may allow a more clear description
of the vascular patterns [168]. Good prospects come from new techniques such as probe-
based confocal laser endomicroscopy which can provide an in situ diagnosis of malignancy
if used in conjunction with any endoscopic technique.
5. Probe-based Confocal Laser Endomicroscopy (pCLE)
Gastrointestinal applications of pCLE are numerous, the system being successfully tested
in real-life conditions [175]. It can be used for identifying premalignant lesions otherwise
invisible to classic endoscopic techniques, such as Barrett’s esophagus [176], classification
of  polipous lesions at  colonic  level  [177],  gastric  metaplasia  or  early  stage lesions  at  all
levels of the digestive tracts [178, 179]. The technique requires injection of fluorescein or
another fluorophore, followed by endoscopic imaging of the dye to identify mucosal de‐
tails such as mucosal and vessel architecture to distinguish among normal, dysplastic, and
neoplastic tissue. The use of fluorescein as an in-vivo contrast agent for detecting vascular
structures has been deemed safe by several studies [180]. It thus allows for better visuali‐
zation of vascular structures, serving as an overall tissue contrasting agent as it may leak
beyond capillary confinement.
The imaging microprobe is  connected to  30,000  fiber-optic  threads  that  enable  point-to-
point real-time detection at 12 frames/sec. The microprobe’s flexibility and size (1.5 mm in
diameter) allow for great user maneuverability to scan tissues in situ at angles that would
not be possible with any available confocal microscope objective. The mini-probe is insert‐
ed through a working channel of any standard bronchoscope and can reach the alveolar
duct. A laser generator emits 488 nm blue argon laser light which is transmitted through
the optical fibers and excites the elastin scaffold of the acinus. In turn, a real time image
of the elastic fibers which sustain the alveoli, as well as the microvessel architecture is re‐
vealed. The probe can be translated over a larger tissue sample, and the images later re‐
constructed in order to extend the field of view covered [181]. A monitor attached to an
imaging unit is available for real-time visualization of cellular images, the device being ca‐
pable of recording full length movies which can be recorded and later on analyzed with
dedicated software [182].
This technology is still in its early stages; however, it was deemed safe by regulatory organ‐
isms in the United States of America for applications in patient settings. In conjunction with
safe contrasting agents such as fluorescein [183] or methilen blue [184], it can be used for the
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in vivo histologic assessment of the bronchial epithelium at all levels of the airway system
[185–187]. Several studies reported good initial results in control groups of healthy smokers
or patients with chronic obstructive pulmonary disease for diagnosing various forms of pa‐
renchymal lung disease [188, 189]. A pCLE investigation seems to be a quick and safe proce‐
dure for patients with various pulmonary conditions, with minimal side-effects related to
both the technique and the contrasting fluorescent agents used for imaging. General consen‐
sus is that further studies are needed in order to extent the diagnostic capabilities and en‐
hance its sensibility in comparison with standard cytological and histological techniques.
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